GLP-1 medications, while effective for weight loss and improving metabolic health, may also lead to emotional flatness in some users, described as the 'meh' effect. This phenomenon involves a reduction in pleasure and engagement with activities, potentially linked to changes in…
The Health Products Regulatory Authority (HPRA) has confirmed over 1,500 reports of suspected adverse reactions related to anti-obesity medications, including serious gastrointest…
Recent research highlights the potential benefits of GLP-1 receptor agonists, commonly used for diabetes and obesity management, suggesting they may also lower the risk of age-rel…
A new clinical trial aims to investigate whether a gradual reduction in semaglutide dosage before complete cessation can lead to better weight maintenance and cardiometabolic outc…
Dr. Gabrielle Lyon, a pioneer in muscle-centric medicine, argues that skeletal muscle is crucial for metabolic health and longevity, challenging conventional weight-loss wisdom. H…
The FDA is reviewing seven unapproved peptides that have gained popularity for their purported health benefits, including weight loss and chronic disease management. The review co…
A recent analysis highlights the importance of lifestyle interventions, including nutrition, physical activity, and stress management, for successful long-term weight maintenance.…
As GLP-1 medications like Wegovy and Mounjaro gain popularity for weight loss, concerns arise about the potential for yo-yo dieting once treatment stops. Evidence suggests that ma…
Recent discussions highlight the potential for yo-yo dieting associated with GLP-1 weight-loss medications like Wegovy and Mounjaro. While these drugs can be effective in aiding w…